COVID-19 Clouds Eye Drug Sales at Novartis
And Beovu's Future Looks Bleak Already
Despite the impact from COVID-19, Novartis performed strongly in the second quarter "demonstrating resilience and agility of our associates and operations," according to CEO Vas Narasimhan. However, there is cause for concern at its ophthalmogy business and those problems are certainly not all down to coronavirus.
